Welcome to CardioVax

 

Founded in 2005, CardioVax has evolved from innovative discoveries at the Lund University Hospital, Malmö (LUHM) and Cedars-Sinai Medical Center (CSMC).  CardioVax is dedicated to advancing these technologies from discovery to routine clinical practice and is committed to developing novel products to treat cardiovascular disease caused by atherosclerosis, an accumulation of fatty deposits within the walls of blood vessels.

 

The role of immune responses in atherosclerosis has been the focus of increasing scientific investigation.  It is now understood that the initiation and progression of atherosclerosis is modulated by the balance between opposing immune responses, i.e, athero-protecting and athero-promoting.  CardioVax’ lead product (CVX-210-H) has been formulated to blunt the athero-promoting responses and to heighten the athero-protecting responses.  In the well established animal model, CVX-210-H has been shown to reduce the progression of atherosclerosis by more than 60% in treated animals versus untreated animals.

 

Dr. Jan Nilsson (LUHM) and Dr. Prediman K. Shah (CSMC) have collaborated for more than 10 years on research programs to elucidate the mechanisms of action and identify promising pharmaceutical products for active immunization against atherosclerotic cardiovascular disease.  CardioVax has no laboratories of its own; the company provides support to CSMC and LUHM in the form of sponsored research agreements and the company’s fundamental discovery and research are performed at these centers. 

 

Based largely on the insights gained through research by the groups of Drs. Shah and Nilsson, CardioVax has developed a lead product candidate, CVX-210-H.  CVX-210-H is comprised of peptide fragment p210 (amino acid residues 3136-3155) of human apolipoprotein B-100 conjugated to recombinant human serum albumin and formulated with aluminum hydroxide colloid gel.  CVX-210-H is being developed as an immune modulating therapy to be administered to patients with atherosclerotic cardiovascular disease to reduce the risk of major cardiovascular events.